← Comparing 2 hypotheses side-by-side
Add hypothesis:
— Select a hypothesis to add —
Closed-loop transcranial focused ultrasound to restore hippo (PVALB) — 1.00 Closed-loop tACS targeting EC-II SST interneurons to block t (SST) — 1.00 Closed-loop focused ultrasound targeting EC-II SST interneur (SST) — 1.00 Closed-loop transcranial focused ultrasound with 40Hz gamma (PVALB) — 1.00 Metabolic Reprogramming to Reverse Senescence (SIRT1,PGC1A,NAMPT) — 1.00 Hippocampal CA3-CA1 synaptic rescue via DHHC2-mediated PSD95 (BDNF) — 0.99 Closed-loop tACS targeting EC-II PV interneurons to suppress (PVALB) — 0.99 SASP Modulation Rather Than Cell Elimination (NFKB1,IL1B,BDNF) — 0.98 Beta-frequency entrainment therapy targeting PV interneuron- (SST) — 0.98 Hypothesis 7: SST-SST1R/Gamma Entrainment-Enhanced Astrocyte (SST, SSTR1, SSTR2) — 0.97 Closed-loop tACS targeting EC-II parvalbumin interneurons to (PVALB) — 0.97 TREM2-Dependent Astrocyte-Microglia Cross-talk in Neurodegen (TREM2) — 0.96 Closed-loop transcranial focused ultrasound targeting EC-II (SST) — 0.94 Dual-Receptor Antibody Shuttling (?) — 0.94 PLCG2 Allosteric Modulation as a Precision Therapeutic for T (PLCG2) — 0.94 SASP-Driven Microglial Metabolic Reprogramming in Synaptic P (HK2/PFKFB3) — 0.93 Closed-loop optogenetic targeting PV interneurons to restore (PVALB) — 0.93 Closed-loop transcranial alternating current stimulation to (SST) — 0.93 Autophagy-Senescence Axis Therapeutic Window (ATG7,BCL2,BCL2L1) — 0.92 Closed-loop tACS targeting entorhinal cortex layer II SST in (SST) — 0.92 Palmitoylethanolamide-Based Endocannabinoid Therapy (PPARA) — 0.92 Closed-loop focused ultrasound targeting CA1 PV interneurons (PVALB) — 0.92 TREM2-mediated microglial tau clearance enhancement (TREM2) — 0.92 Chromatin Remodeling-Mediated Nutrient Sensing Restoration (SMARCA4) — 0.91 Closed-loop transcranial focused ultrasound targeting EC-II (SST) — 0.91 Closed-loop transcranial focused ultrasound to restore hippo (CCK) — 0.91 Alpha-gamma cross-frequency coupling enhancement to restore (SST) — 0.91 TREM2-ASM Crosstalk in Microglial Lysosomal Senescence (SMPD1) — 0.91 sTREM2 as Biomarker of Cystatin-C Therapeutic Efficacy (?) — 0.91 Closed-loop transcranial focused ultrasound to restore hippo (SST) — 0.90
Add
|
× Hypothesis 3: HepaCAM-Con × LRP1-Dependent Tau Uptake
HEPACAM1, HEPACAM2 · neurodegeneration · -
Composite 0.762
Price $0.75
Evidence For 3
Evidence Against 8
Healthy astrocytes secrete neuroprotective factors via extracellular vesicles (EVs), with HepaCAM representing a critical EV cargo protecting against excitotoxic motor neuron death. Inflammatory cytokines disrupt astrocyte exosomal HepaCAM packaging, releasing EVs that instead promote neuronal vulnerability.
LRP1 · neurodegeneration · therapeutic
Composite 0.979
Price $0.99
Evidence For 4
Evidence Against 3
# LRP1-Dependent Tau Uptake Disruption in Tauopathic Neurodegeneration
## Background and Rationale
The progressive spreading of hyperphosphorylated tau pathology throughout the brain represents a hallmark of Alzheimer's disease and related tauopathies, including progressive supranuclear palsy, corticobasal degeneration, and frontotemporal lobar degeneration with tau inclusions. Central to this spreading mechanism is the intercellular transfer of pathological tau species, wherein diseased neuro
Verdict Summary 9/10
dimensions won
Hypothesis 3: HepaCAM-Containing Extrace
1/10
dimensions won
LRP1-Dependent Tau Uptake Disruption
Radar Chart — 10 Dimensions
Score Breakdown
Dimension Hypothesis 3: HepaCAM-Containi LRP1-Dependent Tau Uptake Disr Mechanistic 0.550 0.000 Evidence 0.480 0.725 Novelty 0.720 0.000 Feasibility 0.350 0.000 Impact 0.500 0.000 Druggability 0.280 0.000 Safety 0.400 0.000 Competition 0.300 0.000 Data 0.520 0.000 Reproducible 0.450 0.000
Evidence Hypothesis 3: HepaCAM-Containing Extracellular Vesicles Supporting Evidence Inflammatory cytokines disrupt astrocyte exosomal HepaCAM-mediated protection against neuronal excitotoxicity in SOD1G93 PMID:39602529 Astrocyte-derived extracellular vesicles induce motor neuron death via miRNA-155-5p in SOD1(G93A) model - demonstrates E PMID:37644868 Regional astrocyte diversity in ALS includes distinct aberrant phenotypes affecting EV cargo PMID:32739211 Contradicting Evidence Astrocyte EVs can be toxic via miRNA-155-5p; contradicts protective EV hypothesis PMID:37644868 HepaCAM is a cell adhesion molecule with predominant expression in liver and brain; mechanism of EV packaging unexplaine PMID:39602529 Codiak BioSciences (engineered exosomes) failed 2023 indicating sector challenges PMID:CODIAK_FAILURE LRP1-Dependent Tau Uptake Disruption Supporting Evidence Astrocytic LRP1 enables mitochondria transfer to neurons and mitigates brain ischemic stroke by suppressing ARF1 lactyla PMID:38906140 Cell Metab 2024 LRP1 is a master regulator of tau uptake and spread. PMID:32296178 Nature 2020 PFKFB2-mediated glycolysis promotes lactate-driven continual efferocytosis by macrophages. PMID:36797420 Nat Metab 2023 LRP1 is a neuronal receptor for α-synuclein uptake and spread. PMID:36056345 Mol Neurodegener 2022 Contradicting Evidence Amyloidosis in Alzheimer's Disease: Pathogeny, Etiology, and Related Therapeutic Directions. PMID:35209007 Evolution of blood-brain barrier in brain diseases and related systemic nanoscale brain-targeting drug delivery strategi PMID:34522589 Role of Blood-Brain Barrier in Alzheimer's Disease. PMID:29782323 Price History Overlay
Shared Evidence
No shared papers found across 0 total unique citations. These hypotheses draw from independent evidence bases.
Knowledge Graph Comparison
Hypothesis 3: HepaCAM-Containing Extrace
2 edges
Top Relations promoted: Hypothesis 7: SST-SST1R/Gamma Entrainment-Enhanced Astrocyte Secretome 1
promoted: Hypothesis 4: Metabolic Coupling via Lactate-Shuttling Collapse 1
LRP1-Dependent Tau Uptake Disruption
136 edges
Top Node Types gene 120
mechanism 14
pathway 1
disease 1
Top Relations co_discussed 48
co_associated_with 22
regulates 15
associated_with 8
therapeutic_target 7